The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | Novel biomarkers of response to immunotherapies in multiple myeloma
Samir Parekh, MD, Icahn School of Medicine, Mount Sinai, New York City, NY, discusses his talk on novel biomarkers of response to immunotherapies in multiple myeloma (MM), highlighting a myeloid-derived suppressive cytokine called S100A8/A9, which predicts poor outcomes to CAR T-cell therapy. Inhibiting this cytokine using an antibody has been shown to restore CAR-T functionality in vitro, which may provide direction for future treatment strategies. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So today I gave a talk on novel biomarkers of response to immunotherapies and we have in collaboration with Dr Amit Verma and Mani Mohindru at Roshon Therapeutics and the Albert Einstein College of Medicine discovered a new and exciting biomarker for response to CAR-T in the bone marrow and blood of patients with multiple myeloma. This is a myeloid-derived suppressive cytokine called S100A8/A9...
So today I gave a talk on novel biomarkers of response to immunotherapies and we have in collaboration with Dr Amit Verma and Mani Mohindru at Roshon Therapeutics and the Albert Einstein College of Medicine discovered a new and exciting biomarker for response to CAR-T in the bone marrow and blood of patients with multiple myeloma. This is a myeloid-derived suppressive cytokine called S100A8/A9. And indeed, our studies suggest that an elevated level of this molecule predicts poor outcomes in patients. And along with in vitro studies, we have actually tested an antibody that inhibits the cytokine and in fact restores CAR-T functionality. This is indeed exciting as we think this can be combined with CAR-T’s and even bispecific antibodies to improve outcomes for patients with multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
